|
BioMimetic Therapeutics Posts Webcast re: Second Quarter 2006 Financial Results
Franklin, Tenn. – August 7, 2006 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) released its second quarter 2006 earnings results after market close on Wednesday, August 9, 2006, and hosted a conference call and audio webcast at 5:00 EDT the same day. Dr. Samuel E. Lynch, president and CEO, and Larry Bullock, CFO, discussed the Company's second quarter financial results as well as product development programs and business activities. A live webcast of the conference has been posted on the Investor Relations section of this website. The webcast will be archived for at least 30 days following the call.About BioMimetic Therapeutics BioMimetic Therapeutics, Inc. is developing and commercializing bio-active drug-device combination products for the healing of musculoskeletal injuries and disease, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S ®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. For further information, contact Kearstin Patterson, manager corporate communications, at 615-236-4419. |